-
1دورية أكاديمية
المؤلفون: Kyaw, Moe H, Spinardi, Julia Regazzini, Jagun, Oladayo, Franco Villalobos, Conrado, Kapetanakis, Venediktos, Sharf-Williams, Ruth, Yarnoff, Benjamin
مصطلحات موضوعية: Infectious diseases
وصف الملف: text/html
العلاقة: http://bmjopen.bmj.com/cgi/content/short/14/1/e081019Test; http://dx.doi.org/10.1136/bmjopen-2023-081019Test
الإتاحة: https://doi.org/10.1136/bmjopen-2023-081019Test
http://bmjopen.bmj.com/cgi/content/short/14/1/e081019Test -
2دورية أكاديمية
المؤلفون: Kim, Tae Min, Girard, Nicolas, Leighl, Natasha B, Sabari, Joshua, Rahhali, Nora, Schioppa, Claudio A, Diels, Joris, Sermon, Jan, Chandler, Conor, Kapetanakis, Venediktos, Jain, Ruhee, Li, Tracy, Sanden, Suzy Van
المصدر: Future Oncology ; volume 20, issue 8, page 447-458 ; ISSN 1479-6694 1744-8301
-
3دورية أكاديمية
المؤلفون: Critchlow, Simone, Bullement, Ash, Crabb, Simon, Jones, Robert, Christoforou, Katerina, Amin, Amerah, Xiao, Ying, Kapetanakis, Venediktos, Benedict, Ágnes, Chang, Jane, Kearney, Mairead, Eccleston, Anthony
المساهمون: Pfizer, The healthcare business of Merck KGaA
المصدر: Future Oncology ; volume 20, issue 8, page 459-470 ; ISSN 1479-6694 1744-8301
-
4دورية أكاديمية
المؤلفون: Critchlow, Simone, Bullement, Ash, Crabb, Simon, Jones, Robert, Christoforou, Katerina, Amin, Amerah, Xiao, Ying, Kapetanakis, Venediktos, Benedict, Ágnes, Chang, Jane, Kearney, Mairead, Eccleston, Anthony
وصف الملف: text
العلاقة: https://eprints.soton.ac.uk/481367/1/critchlow_et_al_2023_cost_effectiveness_analysis_for_avelumab_first_line_maintenance_treatment_of_advanced_urothelial.pdfTest; Critchlow, Simone, Bullement, Ash, Crabb, Simon, Jones, Robert, Christoforou, Katerina, Amin, Amerah, Xiao, Ying, Kapetanakis, Venediktos, Benedict, Ágnes, Chang, Jane, Kearney, Mairead and Eccleston, Anthony (2023) Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology. (doi:10.2217/fon-2023-0372 ).
-
5دورية أكاديمية
المؤلفون: Masarova, Lucia, Verstovsek, Srdan, Palandri, Francesca, Mesa, Ruben, Harrison, Claire, Dobi, Balazs, Gorsh, Boris, Wang, Zhaohui, Ellis, Catherine, Patnaik, Dwaipayan, Kapetanakis, Venediktos
المصدر: HemaSphere ; volume 7, issue S3, page e1863563 ; ISSN 2572-9241
-
6دورية أكاديمية
المؤلفون: Su, Po‐Jung, Xiao, Ying, Lin, Amy Y., Goh, Connie, Wu, Ethan, Liu, Kevin, Chou, Patrick, Kuo, Kaitlin, Palencia, Roberto, Chang, Jane, Kearney, Mairead, Kapetanakis, Venediktos, Benedict, Agnes
المساهمون: Pfizer
المصدر: Cancer Reports ; volume 6, issue 10 ; ISSN 2573-8348 2573-8348
-
7رسالة جامعية
-
8دورية أكاديمية
المؤلفون: Kolotourou, Maria, Radley, Duncan, Chadwick, Paul, Smith, Lindsey Rachel, Orfanos, Stavros, Kapetanakis, Venediktos, Singhal, Atul, Cole, Tim J., Sacher, Paul M.
المساهمون: Mytime MEND
مصطلحات موضوعية: childhood obesity
العلاقة: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728723Test/; Kolotourou M, Radley D, Chadwick P, Smith L, Orfanos S, Kapetanakis V, Singhal A, Cole TJ, Sacher PM (2013) 'Is BMI alone a sufficient outcome to evaluate interventions for child obesity?', Childhood Obesity, 9 (4), pp.350-356.; http://hdl.handle.net/10547/625611Test; Childhood Obesity; PMC3728723
-
9دورية أكاديمية
المؤلفون: Cordoba, Raul, Prawitz, Thibaud, Westley, Tracy, Sharma, Anuj, Ambarkhane, Sumeet, Kapetanakis, Venediktos, Sabatelli, Lorenzo
المساهمون: Incyte Corp
المصدر: Advances in Therapy ; volume 39, issue 6, page 2668-2687 ; ISSN 0741-238X 1865-8652
مصطلحات موضوعية: Pharmacology (medical), General Medicine
-
10دورية أكاديمية
المؤلفون: Prawitz, Thibaud, Popat, Rakesh, Suvannasankha, Attaya, Sarri, Grammati, Hughes, Rachel, Wang, Feng, Hogea, Cosmina, Ferrante, Shannon Allen, Gorsh, Boris, Willson, Jenny, Kapetanakis, Venediktos
المساهمون: Medicine, School of Medicine
المصدر: PMC
مصطلحات موضوعية: Belamaf, Indirect treatment comparison, Matching-adjusted, Selinexor, Survival
وصف الملف: application/pdf
العلاقة: Advances in Therapy; Prawitz T, Popat R, Suvannasankha A, et al. DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma. Adv Ther. 2021;38(11):5501-5518. doi:10.1007/s12325-021-01884-7; https://hdl.handle.net/1805/39836Test